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&
Abstract&
With$rare$exceptions,$NonLHodgkin$Lymphoma$(NHL)$remains$a$fatal$disease$in$dogs$and$
cats.$$Although$our$understanding$of$the$disease$continues$to$grow$through$research,$the$
impact$of$this$research$has$yet$to$be$translated$into$significant$increases$in$survival$times$for$
affected$patients.$$To$highlight$the$importance$of$this$disease,$the$editorial$team$of$
Veterinary$and$Comparative$Oncology$have$constructed$this$themed$issue$highlighting$
current$research$in$this$field.$$This$short$introductory$review$aims$to$provide$a$synopsis$of$
some$of$the$key$areas$of$global$research$interest,$identify$the$challenges$to$clinical$progress$
and$finally$will$offer$an$optimistic$view$of$new$developments$which$aim$to$enhance$the$lives$
of$our$patients.$
&
Introduction&
Non$Hodgkin$Lymphoma$(NHL)$remains$one$of$the$most$important$diseases$in$human$and$
veterinary$oncology.$$Despite$incremental$advances$in$our$understanding$of$lymphoma$
biology$and$treatment,$the$disease$remains$one$of$high$mortality$in$veterinary$species.$$In$
dogs,$NHL$accounts$for$approximately$10%$of$all$malignant$tumours$and$83%$of$all$
haematopoietic$malignancies$1.$NHL$is$initially$highly$responsive$to$standard$chemotherapy,$
as$with$human$patients,$with$firstLremission$rates$of$approximately$90%;$however,$drug$
resistance$occurs$in$most$cases,$resulting$in$disease$recurrence1.$$Our$understanding$of$this$
disease$in$dogs$and$cats$has$significantly$lagged$behind$human$medicine$in$terms$of$
pathophysiology$of$the$disease,$classification,$diagnosis$and$novel$treatment$options.$$
However,$with$advances$in$molecular$biology,$pathology$and$genetics,$we$are$developing$
the$toolbox$necessary$to$explore$this$disease$more$fully.$$In$addition,$international$
collaborative$groups$are$developing,$such$as$the$European$Lymphoma$Network2,$helping$to$
drive$research$forward$through$increasing$critical$research$mass.$$Importantly,$collaborative$
research$and$the$development$of$molecular$and$immunological$toolboxes$are$allowing$the$
dog$and$cat$to$be$explored$as$significant$and$important$models$of$human$lymphoma$biology$
and$therapy.$$$
In$studying$the$literature$around$canine$and$feline$NHL,$and$bringing$together$key$
publications$in$this$issue$of$VCO,$it$becomes$easier$to$crystallize$some$of$the$greatest$clinical$
challenges$to$improving$outcomes$in$this$devastating$disease.$$However,$the$exponential$
increase$in$our$understanding$of$cancer$biology$and$the$overt$collaborative$approaches$to$
advancing$knowledge$offers$an$optimistic$view$of$Lymphoma$research,$ensuring$that$the$
following$challenges$can$be$transformed$into$significant$opportunities.$
&
Establishing&an&Appropriate&Clinical&and&Pathological&Classification&System&
One$of$the$major$hurdles$to$enhancing$clinical$development$has$been$our$inability$to$
develop$a$good$subLclassification$system$for$NHL,$similar$to$that$for$people.$$As$far$back$as$
1966,$veterinarians$have$tried$to$apply$the$human$classification$systems$to$canine$NHL3L7.$$In$
order$to$use$all$diagnostic$criteria$such$as$cellular$morphology,$cell$lineage,$topography$and$
biology,$the$Revised$EuropeanLAmerican$Classification$of$Lymphoid$Neoplasms$(REAL)$was$
created$which$led$to$the$currently$used$World$Health$Organization$(WHO)$system$of$
classification8L10.$$The$application$of$standardised$criteria$to$differentiate$different$types$of$
Canine$malignant$lymphoma$showed$an$accuracy$of$83%$amongst$17$different$
pathologists11.$$Feline$lymphomas$have$also$been$classified$according$to$the$National$Cancer$
Institute$working$formulation$(NCI$WF)12.&
In$addition$to$marker$classification$systems,$anatomic$location$remains$an$important$
consideration$with$regards$to$prognosis$and$treatment$options$for$dogs$and$cats.$
Multicentric$lymphoma$is$the$most$common$form$in$dogs,$followed$by$the$alimentary$form$
and$other$types.$A$poorer$prognosis$has$been$assigned$to$the$gastrointestinal$form,$
compared$to$the$multicentric$presentation13,14.$$The$anatomic$location$of$lymphoma$in$cats$
has$changed$significantly$over$the$last$2$decades$with$an$increasingly$high$rate$of$
gastrointestinal$lymphoma$accompanied$by$a$decreased$FeLV/FIV$prevalence.$Despite$the$
decrease$in$this$latter$negative$prognostic$factor,$gastrointestinal$lymphomas$still$have$
short$overall$responses$even$on$multiLagent$chemotherapy15.$$
The$importance$of$an$internationally$recognised$classification$system$for$lymphoma$cannot$
be$overstated,$as$the$current$systems$are$still$far$from$perfect.$$$It$is$essential$that$the$
oncology$community$develop$such$systems$to$further$identify$different$disease$entities$in$
companion$animals$and$to$assign$prognostic$value$to$specific$tumour$types.$For$example,$
indolent$lymphoma$has$been$shown$to$behave$in$a$different$manner$than$highLgrade$
lymphomas$and$therefore$require$a$different$treatment$approach16,17.$$
The$use$of$immunological$markers$and$gene$and$protein$profiling$is$underpinning$a$
revolution$in$developing$classification$systems$for$cancer$that$will$inform$treatment$and$
prognosis.$$The$introduction$of$gene$expression$profiling$in$human$medicine$has$identified$
novel$molecular$lymphoma$subtypes$that$are$histologically$indistinguishable18.$In$diffuse$
large$BLcell$lymphoma$(DLBCL),$the$distinction$of$the$germinal$center$BLcell–like$(GCB)$
DLBCL$and$activated$BLcell–like$(ABC)$DLBCL$subtypes$is$beginning$to$translate$into$the$
clinic,$as$these$diagnostic$categories$have$significantly$different$survival$rates$after$standard$
treatment.$Similarly,$the$molecular$distinction$using$gene$expression$profiling$of$DLBCL$and$
Burkitt’s$lymphoma$(BL)$is$of$major$clinical$importance,$as$BL$requires$more$intensive$
treatment$strategies.$These$examples$evidence$that$the$routine$application$of$gene$
expression$profiling$in$veterinary$species$may$eventually$lead$to$the$establishment$of$the$
molecular$classification$of$lymphoma.$$Gene$expression$profiling$has$been$performed$in$
canine$lymphoma1.$$However,$many$of$the$current$studies$in$veterinary$medicine$suffer$
from$low$patient$numbers$and$insufficient$power.$$Developing$a$robust$classification$system$
based$upon$molecular$signatures$combined$with$pathological$and$clinical$criteria$will$
require$significant$international$collaboration.$$This$collaboration$needs$to$be$extended$to$
data$scientists$to$develop$appropriate$models$and$algorithms$that$can$be$translated$into$
clinical$practice.$
&
Understanding&Molecular&Pathophysiology&
Cancer$is$a$difficult$disease$to$define$as$an$entity$but$represents$break$down$in$cellular$
homeostasis$leading$to$unrestricted$growth$and$proliferation$of$tissues19.$$$Much$of$this$
unrestricted$growth$is$driven$by$changes$in$Oncogenes$and/or$Tumour$Suppressor$Genes$
that$control$cellular$processes.$$The$NHLs$represent$a$heterogeneous$group$of$malignancies$
that$arise$from$the$lymphoid$system$and,$as$with$other$cancers,$have$been$explained$
through$the$concept$of$multistage$carcinogenesis.$$In$recent$years,$the$cancer$stem$cell$
hypothesis$(where$a$cancer$is$driven$by$a$small$subLpopulations$of$rare$primitive$cancer$
stem$cells)$has$been$used$to$explain$the$formation$of$many$solid$cancers20.$$However,$no$
lymphoma$stem$cell$pool$has,$as$yet,$been$defined$in$lymphoma.$$The$pathophysiology$of$
lymphoma$is$more$likely$closely$linked$with$B$and$T$cell$development$and$a$revolution$in$
molecular$biology$techniques$is$allowing$this$to$be$dissected$in$human$and$veterinary$
medicine.$$$
The$development$of$both$T$and$B$cells$lends$itself$to$the$potential$for$DNA$damage.$$As$an$
example,$BLcell$development$begins$in$the$primary$lymphoid$organs$with$subsequent$
differentiation$in$secondary$lymphoid$tissues$such$as$lymph$nodes,$spleen,$or$tonsils18.$$$
During$development$B$cells$are$subjected$to$a$range$of$DNA$modifications$that$could$
predispose$to$the$development$of$lymphoma.$$B$cell$development$in$the$bone$marrow$is$
initiated$during$the$development$of$the$B$cell$receptor$through$V(D)J$recombination.$$BCR$
expression$is$followed$by$the$exit$of$B$cells$from$the$bone$marrow$to$become$naïve$B$cells.$$
Activation$of$B$cells$through$interaction$with$antigen$leads$to$germinal$centre$activation$
involving$somatic$hypermutation$(SHM)$and$classLswitch$recombination$(CSR).$$Finally,$there$
is$the$production$of$B$cells$and$memory$cells.$$V(D)J$recombination,$SHM,$and$CSR$especially$
represent$critical$processes$which$could$predispose$to$these$malignancies$and$all$have$been$
linked$to$lymphomagenesis18.$$
$
Diffuse$Large$B$Cell$Lymphoma$(DLBCL)$represents$the$most$common$type$of$malignant$
lymphoma$in$both$human$and$veterinary$medicine1.$DLBCL$is$heterogeneous$with$respect$to$
clinical$presentation$and$pathology$but$molecularly$can$fall$into$distinct$subLclasses.$$In$a$
generation$we$have$gone$from$single$pathway$analysis$to$a$position$when$we$can$examine$
thousands$of$genetic$changes$in$a$cancer$sample$using$gene$array$“chips”$or$newer$
technologies$such$as$high$throughput$sequencing$and$RNA$sequencing$(RNALseq).$$RNALseq$
uses$Next$Generation$Sequencing$(NGS)$to$rapidly$analyze$the$changing$transcriptome$in$a$
cancer$cell.$$These$technologies$in$cancer$discovery$have$been$used$to$Identify$common$
cancer$signatures$across$lymphoma$phenotypes$and$Identify$potential$targets$for$drug$
development21.$$In$human$oncology,$Array$profiling$has$identified$three$molecular$subtypes$
Activated$BLcell–like$diffuse$(ABC),$Germinal$Center$BLcell–like$(GCB)$and$Primary$
Mediastinal$BLcell$lymphoma$(PMBL).$$These$subtypes$use$distinct$oncogenic$signaling$
pathways$and$respond$differently$to$conventional$treatment.$$In$canine$Lymphoma$we$have$
identified$distinct$molecular$subLtypes,$which$resemble$ABC$and$GCB$types1,$but$more$work$
is$required$to$characterize$these$subtypes$with$much$larger$numbers$of$patients.$$By$
building$a$toolbox$of$reagents$and$genetic$profiles,$and$with$international$and$national$
collaborative$research,$it$will$be$possible$to$generate$the$numbers$of$patients$required$to$
advance$our$understanding$of$the$molecular$pathology$of$this$disease.$$This$will$help$us$
define$patients$that$require$conventional$treatments$to$be$tailored,$and$potentially$identify$
new$therapeutic$targets$or$biomarkers$for$diagnosis$and$early$relapse.$$
 
Developing&New&Treatments&and&Overcoming&Drug&Resistance&
In$Veterinary$and$Human$Lymphoma$treatment,$conventional$cytotoxic$chemotherapy$is$the$
mainstay$of$current$therapies.$$These$are$largely$based$on$the$CHOP$(Cyclophosphamide,$
Doxorubicin,$Vincristine$and$Prednisolone)$protocols$and,$in$veterinary$oncology,$very$little$
has$changed$in$the$last$20$years$in$terms$of$advancing$treatment$options$or$improving$
survival$times.$$The$major$significant$change$has$been$the$adoption$of$shorter$protocols,$
removing$the$maintenance$phase$of$treatment22$and$studies$to$evaluate$whether$shorter$
protocols$are$possible$without$significant$effects$on$mean$survival$time$(MST)23,24.$$
Veterinary$chemotherapy$protocols$are$rarely$curative$as$significant$changes$in$
chemotherapy$intensity$often$have$the$negative$effect$of$reducing$overall$quality$of$life.$$In$
addition,$the$development$of$multiLdrug$resistance$is$often$an$inevitable$consequence$of$
conventional$chemotherapy$treatments,$obviating$the$need$for$new$approaches.$
New$approaches$will$require$the$development$of$new$therapies$and/or$the$development$of$
technologies$for$overcoming$drug$resistance.$Cytotoxic$chemotherapy$drugs$have$
traditionally$been$administered$based$on$the$Maximally$Tolerated$Dose$(MTD)$principle25,26$$
but$the$development$of$chemotherapyLresistant$cells$and$tumour$recurrence$or$relapse$
seem$to$be$an$inevitable$consequence$of$the$“Darwinian”$tumour$evolution.$$High$dose$
chemotherapy,$which$targets$the$chemotherapyLsensitive$cells,$actually$allows$the$
population$of$resistant$cells$to$expand,$a$process$known$as$“competitive$release”.$$$
Overcoming$competitive$release$using$alternative$treatment$approaches$is$an$active$area$of$
research$in$human$medicine$and$is$yet$to$be$exploited$in$veterinary$oncology.$$As$an$
example,$ATPLbinding$cassette$(ABC)$drug$transporters$consuming$ATPs$for$drug$efflux$is$a$
common$mechanism$by$which$cancer$develops$multidrug$resistance$(MDR).$$NonL
chemotherapy$drugs$that$are$ABC$substrates$(“ersatzdroges”)$are$being$explored$as$a$
means$to$suppress$MDR$phenotypes27L29.$
The$development$of$small$molecule,$targeted$drugs$has$been$seen$hotly$pursued$in$human$
oncology,$especially$drugs$that$target$the$kinome.$$To$date,$there$are$only$two$tyrosine$
kinase$inhibitors,$licensed$for$the$use$in$dogs.$$These$drugs$have$largely$been$used$for$
treating$mast$cell$tumours$(with$cLkit$mutations),$but$they$have$also$shown$effects$in$other$
cancers30.$$Alternatively$drugs$such$as$CDKLinhibitors$are$being$explored$in$solid$cancers.$
CDK$is$essential$for$the$progression$of$the$cell$cycle,$which$means$it$could$represent$a$
treatment$target$within$rapidly$growing$tumour$cells.$Currently$trials$are$ongoing$in$human$
medicine$incorporating$CDK$inhibitors$as$treatment$for$solid$tumours$and$nonLHodgkin$
lymphoma31,32.$The$role$that$these$drugs$play$in$canine$and$feline$lymphoma$is$yet$to$be$
realized,$but,$as$with$conventional$drugs,$the$selection$pressure$created$by$using$one$single$
drug$supports$the$development$of$drug$resistance.$$With$no$veterinary$secondLgeneration$
drugs$on$the$horizon,$and$with$the$development$of$resistance,$the$benefits$from$these$
drugs$are$potentially$shortLlived.$$
The$development$of$small$molecules$to$target$specific$pathways$and$driver$mutations$was$
considered$to$be$a$major$breakthrough$in$cancer$treatments.$$However,$monoclonal$
antibodies$have$now$far$exceeded$small$molecules$in$terms$of$the$market$share$of$biologics$
being$used$in$cancer$treatment.$$In$human$medicine$monoclonal$antibodies$have$meant$a$
breakthrough$in$lymphoma,$with$significantly$improved$outcomes$targeting$CD20$
expression33.$CD20$is$a$cluster$of$differentiation$molecule$consistency$expressed$on$the$
human$B$lymphocyte$cell$membrane,$with$the$antiLCD20$monoclonal$antibody$rituximab$
now$approved$in$drug$protocols.$Rituximab$does$not$bind$canine$CD20,$driving$a$need$to$
develop$canineLspecific$antibodies.$$The$use$of$“human”$monoclonal$antibodies$in$
veterinary$oncology$is$usually$not$feasible$due$to$the$development$of$an$immune$response$
to$foreign$protein$but$speciesLspecific$$(e.g.$caninized)$monoclonal$antibodies$are$being$
developed$for$canine$lymphoma34.$$This$is$a$truly$exciting$prospect,$as$it$will$deliver$new$and$
affordable$reagents$to$the$veterinary$oncology$community35,36.$
&
Horizon&Scanning&and&Precision&Medicine&
The$tools$that$have$or$are$being$developed$for$dissecting$the$lymphoma$genome$offers$an$
incredible$opportunity$to$refine$our$understanding$of$this$devastating$disease.$$$However,$as$
an$oncology$community$we$must$form$strong$collaborations$across$the$disciplines$in$order$
to$exploit$the$vast$amount$of$data$we$now$have$the$ability$to$generate.$$Currently,$the$
amount$of$data$we$are$generating$far$exceeds$our$ability$to$analyze$and$understand$it,$
impeding$progress$in$diagnosis,$classification$of$the$disease$and$treatment.$$$
As$discussed,$the$development$of$the$appropriate$reagents$for$mining$veterinary$genomes,$
proteomes$and$metabolomes$is$rapidly$expanding,$coupled$with$a$reduction$in$costs.$$To$
fully$exploit$these$technologies$we$must$improve$clinical$data$recording,$consider$largeL
scale$multicentre$clinical$studies$and$embrace$the$importance$of$bioinformatics,$statistics$
and$mathematical$modelling21.$$This$will$require$a$paradigm$shift$in$how$we$traditionally$
approach$veterinary$medicine,$removing$research$and$discipline$silos$and$mapping$a$
landscape$for$a$“comparative$oncology”$ecosystem.$This$will$involve$developing$systems$
that$will$allow$us$to$integrate$clinical,$biological$and$epidemiological$data$to$provide$the$
optimum$clinical$care$for$our$patients,$i.e.$the$development$of$true$precision$medicine21.$$$$
$
Concluding&remarks&
As$evidenced$by$the$range$of$research$papers$in$this$edition$of$VCO,$there$is$much$cause$for$
optimism$in$the$field$of$lymphoma$research.$$There$are$continuous$improvements$in$
conventional$therapies,$diagnosis,$imaging$and$drug$development$in$veterinary$oncology.$$
Equally,$we$have$an$unparalleled$opportunity$to$study$lymphoma$without$any$species$
boundaries$as$evidenced$by$the$clear$pathological$and$molecular$similarities$of$this$disease$
between$dogs$and$humans1.$$Data$derived$from$studies$in$spontaneous$lymphoma$in$dogs$
and$cats$could$serve$to$improve$animal$health$and$also$serve$as$an$important$link$between$
basic$cancer$research$and$human$and$veterinary$clinical$trials.$$Creating$such$a$platform$of$
interdisciplinarity$supports$progress$in$clinical$cancer$practice,$offering$an$opportunity$to$
increase$the$predictability$of$human$clinical$trails$and$reduce$the$cost$and$time$of$getting$
new$drugs$into$patients.$
Our$exponential$growth$in$understanding$of$the$molecular$events$in$lymphoma$is$being$
matched$by$the$development$of$exciting$therapeutic$strategies$such$as$speciesLspecific$
monoclonal$antibodies.$$In$addition,$we$are$living$in$a$dataLdriven$age,$which$can$be$
exploited$for$the$good$of$our$patients.$Data$science$will$be$vital$to$understanding$the$
complexity$of$lymphoma$at$the$cell$and$population$level$and$the$integration$of$clinical$and$
biological$data$to$improve$treatment$outcomes$and$design$specific$therapies.$$Precision$
medicine$proposes$the$customization$of$healthcare,$with$medical$decisions,$practices,$
and/or$products$being$tailored$to$the$individual$patient$and$this$should$be$the$direction$of$
travel$for$veterinary$oncology$also.&
&
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